Kummer Christiane, Winkeler Alexandra, Dittmar Claus, Bauer Bernd, Rueger Maria Adele, Rueckriem Benedikt, Heneka Michael T, Vollmar Stefan, Wienhard Klaus, Fraefel Cornel, Heiss Wolf-Dieter, Jacobs Andreas H
Laboratory for Gene Therapy and Molecualr Imaging, Max Planck-Institute for Neurological Research, Center for Molecualr Medicine, and Department of Neurology, University of Cologne, Cologne, Germany.
Mol Imaging. 2007 May-Jun;6(3):181-92.
To develop efficient and safe gene therapy approaches, the herpes simplex virus type 1 thymidine kinase gene (HSV-1-tk) has been shown to function as a marker gene for the direct noninvasive in vivo localization of thymidine kinase (TK) expression by positron emission tomography (PET) using radiolabeled nucleoside analogues as specific TK substrates. Moreover, the gene encoding dopamine type 2 receptor (d2r) could be used as a PET marker gene using specific radiolabeled receptor binding compounds. Here we describe the quantitative colocalization of d2r and HSV-1-tk gene expression mediated from a universal HSV-1 amplicon vector in a subcutaneous human Gli36dEGFR glioma model by PET. The HSV-1 amplicon vector was constructed using a bicistronic gene cassette to contain (1) the d2r80A mutant, which is able to bind its ligand racloprid but unable to activate downstream signal transduction pathways, and (2) the tk39 mutant with enhanced enzymatic activity toward guanosine analogues fused to the green fluorescent protein gene (tk39gfp) serving as a marker gene in cell culture. After infection of human Gli36dEGFR glioma cells with the HSV-d2r80AIREStk39gfp (HSV-DITG) amplicon vector in cell culture, D2 receptor expression and its targeting to the cell surface were determined by Western blotting and immunolabeling. Vector application in vivo served for quantitative colocalization of d2r80A- and tk39gfp-derived PET signals employing the specific D2 receptor binding compound [(11)C]racloprid and the specific TK39 substrate 9-(4-[(18)F]fluoro-3-hydroxymethylbutyl)guanine. Our results demonstrate that for the range of gene expression studied in vivo, both enzymatic and receptor binding assays give comparable quantitative information on the level of vector-mediated gene expression in vivo. The d2r80A in combination with a specific binding compound passing the intact blood-brain barrier might be an alternative marker gene for the noninvasive assessment of vector-mediated gene expression in the brain using PET.
为了开发高效且安全的基因治疗方法,单纯疱疹病毒1型胸苷激酶基因(HSV-1-tk)已被证明可作为标记基因,通过正电子发射断层扫描(PET),利用放射性标记的核苷类似物作为特异性胸苷激酶(TK)底物,在体内直接进行非侵入性定位TK表达。此外,编码多巴胺2型受体(d2r)的基因可利用特异性放射性标记的受体结合化合物用作PET标记基因。在此,我们描述了在皮下人Gli36dEGFR胶质瘤模型中,通过PET对通用HSV-1扩增子载体介导的d2r和HSV-1-tk基因表达进行定量共定位。HSV-1扩增子载体使用双顺反子基因盒构建,包含(1)d2r80A突变体,其能够结合其配体雷氯必利,但无法激活下游信号转导途径,以及(2)对鸟苷类似物具有增强酶活性的tk39突变体,其与绿色荧光蛋白基因(tk39gfp)融合,在细胞培养中用作标记基因。在细胞培养中用HSV-d2r80AIREStk39gfp(HSV-DITG)扩增子载体感染人Gli36dEGFR胶质瘤细胞后,通过蛋白质印迹法和免疫标记法测定D2受体表达及其在细胞表面的靶向性。体内载体应用用于利用特异性D2受体结合化合物[(11)C]雷氯必利和特异性TK39底物9-(4-[(18)F]氟-3-羟甲基丁基)鸟嘌呤对源自d2r80A和tk39gfp的PET信号进行定量共定位。我们的结果表明,对于体内研究的基因表达范围,酶促和受体结合测定都能提供关于体内载体介导的基因表达水平的可比定量信息。d2r80A与能够穿过完整血脑屏障的特异性结合化合物相结合,可能是使用PET对脑内载体介导的基因表达进行非侵入性评估的替代标记基因。